C61 Malignant neoplasm of prostate.
The patient was diagnosed with stage 4 moderately differentiated prostate adenocarcinoma G3 (Gleason 4+3=7) with metastases in bones and lungs.
Surgery (orchiectomy), hormone therapy (Prednisolone, Enzalutamide), chemotherapy (Docetaxel, Cabazitaxel).
Patients diagnosed at stage 4, five-year survival rate is approximately 29%.
Autologous DCV and CIK. Immunotherapy has been applied since October 2021 to March 2022.
In 2023 the patient has received a course of PTAC.
Stable disease, ongoing hormonotherapy. The patient enjoys life and has only follow-up.